NovaTarg is a research and development company founded by Dr. Ken Batchelor in 2009 for the purpose of discovering innovative medicines to treat metabolic diseases and cancer. NovaTarg’s primary focus is activation of AMPK, a key regulator of energy utilization in cells. Advanced leads have been identified and are being evaluated for drug candidate properties. NovaTarg’s first drug candidate will be for the treatment of type 2 diabetes.